Although the interaction of matrix proteins with integrins is known to initiate signaling pathways that are essential for cell survival, a role for tumor suppressors in the regulation of these pathways has not been established. We demonstrate here that p53 can inhibit the survival function of integrins by inducing the caspase-dependent cleavage and inactivation of the serine/threonine kinase AKT/PKB. Specifically, we show that the α6β4 integrin promotes the survival of p53-deficient carcinoma cells by activating AKT/PKB. In contrast, this integrin does not activate AKT/PKB in carcinoma cells that express wild-type p53 and it actually stimulates their apoptosis, in agreement with our previous findings (Bachelder, R.E., A. Marchetti, R. Falcioni, S. Soddu, and A.M. Mercurio. 1999. J. Biol. Chem. 274:20733–20737). Interestingly, we observed reduced levels of AKT/PKB protein after antibody clustering of α6β4 in carcinoma cells that express wild-type p53. In contrast, α6β4 clustering did not reduce the level of AKT/PKB in carcinoma cells that lack functional p53. The involvement of caspase 3 in AKT/PKB regulation was indicated by the ability of Z-DEVD-FMK, a caspase 3 inhibitor, to block the α6β4-associated reduction in AKT/PKB levels in vivo, and by the ability of recombinant caspase 3 to promote the cleavage of AKT/PKB in vitro. In addition, the ability of α6β4 to activate AKT/PKB could be restored in p53 wild-type carcinoma cells by inhibiting caspase 3 activity. These studies demonstrate that the p53 tumor suppressor can inhibit integrin-associated survival signaling pathways.
Skip Nav Destination
Article navigation
29 November 1999
Article Contents
Article|
November 29 1999
P53 Inhibits α6β4 Integrin Survival Signaling by Promoting the Caspase 3–Dependent Cleavage of Akt/PKB
Robin E. Bachelder,
Robin E. Bachelder
aDivision of Cancer Biology and Angiogenesis, Department of Pathology, Beth Israel Deaconess Medical Center
bHarvard Medical School, Boston, Massachusetts 02215
Search for other works by this author on:
Mark J. Ribick,
Mark J. Ribick
aDivision of Cancer Biology and Angiogenesis, Department of Pathology, Beth Israel Deaconess Medical Center
bHarvard Medical School, Boston, Massachusetts 02215
Search for other works by this author on:
Alessandra Marchetti,
Alessandra Marchetti
bHarvard Medical School, Boston, Massachusetts 02215
Search for other works by this author on:
Rita Falcioni,
Rita Falcioni
cRegina Elena Cancer Institute, Rome, 00158 Italy
Search for other works by this author on:
Silvia Soddu,
Silvia Soddu
cRegina Elena Cancer Institute, Rome, 00158 Italy
Search for other works by this author on:
Kathryn R. Davis,
Kathryn R. Davis
aDivision of Cancer Biology and Angiogenesis, Department of Pathology, Beth Israel Deaconess Medical Center
bHarvard Medical School, Boston, Massachusetts 02215
Search for other works by this author on:
Arthur M. Mercurio
Arthur M. Mercurio
aDivision of Cancer Biology and Angiogenesis, Department of Pathology, Beth Israel Deaconess Medical Center
Search for other works by this author on:
Robin E. Bachelder
aDivision of Cancer Biology and Angiogenesis, Department of Pathology, Beth Israel Deaconess Medical Center
bHarvard Medical School, Boston, Massachusetts 02215
Mark J. Ribick
aDivision of Cancer Biology and Angiogenesis, Department of Pathology, Beth Israel Deaconess Medical Center
bHarvard Medical School, Boston, Massachusetts 02215
Alessandra Marchetti
bHarvard Medical School, Boston, Massachusetts 02215
Rita Falcioni
cRegina Elena Cancer Institute, Rome, 00158 Italy
Silvia Soddu
cRegina Elena Cancer Institute, Rome, 00158 Italy
Kathryn R. Davis
aDivision of Cancer Biology and Angiogenesis, Department of Pathology, Beth Israel Deaconess Medical Center
bHarvard Medical School, Boston, Massachusetts 02215
Arthur M. Mercurio
aDivision of Cancer Biology and Angiogenesis, Department of Pathology, Beth Israel Deaconess Medical Center
Abbreviations used in this paper: CAD, caspase-activated deoxyribonuclease; dnAKT, dominant negative AKT; dnp53, dominant negative p53; GFP, green fluorescent protein; HA, hemagglutinin; tsp53, temperature-sensitive p53.
Received:
May 14 1999
Revision Requested:
October 13 1999
Accepted:
October 18 1999
Online ISSN: 1540-8140
Print ISSN: 0021-9525
© 1999 The Rockefeller University Press
1999
The Rockefeller University Press
J Cell Biol (1999) 147 (5): 1063–1072.
Article history
Received:
May 14 1999
Revision Requested:
October 13 1999
Accepted:
October 18 1999
Citation
Robin E. Bachelder, Mark J. Ribick, Alessandra Marchetti, Rita Falcioni, Silvia Soddu, Kathryn R. Davis, Arthur M. Mercurio; P53 Inhibits α6β4 Integrin Survival Signaling by Promoting the Caspase 3–Dependent Cleavage of Akt/PKB. J Cell Biol 29 November 1999; 147 (5): 1063–1072. doi: https://doi.org/10.1083/jcb.147.5.1063
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionEmail alerts
Advertisement
Advertisement